Open access · CC-BY
via OpenAlex
Nanotechnology for Age-Related Macular Degeneration
Bo Xiong Yang, Ge Li, Jiaxin Liu, Xiangyu Li, Shixin Zhang, Fengying Sun, Wenhua Liu
Pharmaceutics · 2021 · ▲ 30 citations
Abstract
Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/pharmaceutics13122035
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Yang, B.X., Li, G., Liu, J., Li, X., Zhang, S., Sun, F., & Liu, W. (2021). Nanotechnology for Age-Related Macular Degeneration. <em>Pharmaceutics</em>. https://doi.org/10.3390/pharmaceutics13122035
Vancouver
Yang BX, Li G, Liu J, Li X, Zhang S, Sun F, et al. Nanotechnology for Age-Related Macular Degeneration. Pharmaceutics. 2021. doi:10.3390/pharmaceutics13122035.
BibTeX
@article{bo2021Nanote,
title = {Nanotechnology for Age-Related Macular Degeneration},
author = {Bo Xiong Yang and Ge Li and Jiaxin Liu and Xiangyu Li and Shixin Zhang and Fengying Sun and Wenhua Liu},
journal = {Pharmaceutics},
year = {2021},
doi = {10.3390/pharmaceutics13122035},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Expert Opinion on Pharmacotherapy 2008
Citation only
Pharmacotherapy of age-related macular degeneration
EBM Guidelines 2000
Citation only
Age-related macular degeneration (AMD)
Medical University of Vienna 2011
Open access · US-GOV
Comparison of Intravitreal Dexamethasone With Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Monotherapy in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration A Prospective, Randomized, Clinical Study
Zhonghua shiyan yanke zazhi 2019
Citation only
The research status and the limitations of mesenchymal stem cell-based therapies in age-related macular degeneration
Australian journal of general practice 2026
Citation only
Age-related macular degeneration: Updates for general practitioners.
Clinical Interventions in Aging 2017
Open access · CC-BY